查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2045888

罕見疾病基因檢測市場－全球產業規模、佔有率、趨勢、機會、預測：依疾病類型、專業、技術、最終用戶、地區和競爭格局分類，2021-2031年

Rare Disease Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Speciality, By Technology, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球罕見疾病基因檢測市場預計將從 2025 年的 11.1 億美元大幅成長至 2031 年的 18.3 億美元，複合年成長率為 8.69%。

該市場涵蓋專門的診斷服務和檢測，這些服務和檢測分析遺傳物質以識別與罕見疾病相關的突變。推動這一成長的主要因素是基因測序成本的快速下降，以及臨床上迫切需要為面臨複雜漫長診斷過程的患者提供明確的診斷結果。

市場概覽
預測期 2027-2031
市場規模：2025年 11.1億美元
市場規模：2031年 18.3億美元
複合年成長率：2026-2031年 8.69%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

根據Global Genes預測，到2024年，全球將發現超過1萬種罕見疾病和遺傳性疾病，將進一步推動相關服務的需求。儘管市場成長潛力巨大，但報銷和保險覆蓋方面的重大政策障礙常常阻礙市場發展。支付結構不一致和支付方要求嚴格，往往導致理賠被拒或患者需承擔高昂的自付費用，限制了患者獲得必要的診斷資源，並延緩了先進檢測項目的商業性化應用。

市場促進因素

全球罕見疾病基因檢測市場主要受兩大關鍵因素驅動：基因組定序成本的大幅下降和次世代定序（NGS）技術的快速發展。這些技術進步幾乎消除了經濟壁壘，使高通量定序從小眾奢侈品轉變為標準診斷程序。超低成本平台的推出便是這項轉變的標誌，例如Ultima Genomics公司於2024年2月推出的UG 100定序儀，其基因組分析成本低至100美元。這種新的價格優勢正在加速全基因組定序（WGS）的普及，進而導致全球檢體處理量的成長。

這一行業規模的擴張得到了Regeneron遺傳學中心等領先研究機構的支持。截至2024年9月，該中心已成功完成超過250萬個EXOME定序，顯示該領域的處理能力顯著提升。同時，在政府政策的支持下，孤兒藥和伴隨診斷的研發投入增加，也為市場發展提供了助力。隨著監管機構鼓勵開發低發病率疾病的治療方法，製藥公司擴大利用基因檢測來識別罕見突變，並在臨床試驗中有效地對患者進行分層。美國食品藥物管理局（FDA）於2025年1月發布的《2024年新藥認證報告》也印證了這個趨勢。報告顯示，所有新核准藥物中有52%用於治療罕見疾病或孤兒疾病，凸顯了強大的伴隨診斷和基因檢測在為罕見疾病患者提供精準醫療方面發揮的關鍵作用。

市場挑戰

全球罕見疾病基因檢測市場成長的主要障礙是嚴格的報銷政策和不一致的資格標準。保險公司通常將包括全EXOME序 (WES) 和全基因組定序 (WGS) 在內的先進基因組檢測歸類為「實驗性」或「研究用途」。這種分類通常源於認為缺乏足夠的臨床效用數據，導致理賠申請經常被直接拒絕或受到嚴格的預先核准要求。

這些挑戰為診斷檢查室帶來了巨大的財務風險，並導致患者承擔高昂的自付費用。此類行政障礙實際上將先進檢測的可用性與患者就醫途徑脫鉤，阻礙了醫療機構實施能夠解決複雜診斷流程的綜合基因檢測。這些保險糾紛造成的營運摩擦嚴重阻礙了商業性應用。根據美國醫學會 (AMA) 2024 年的一份報告，94% 的醫生因預先核准要求而導致患者照護延誤，這一結構性問題尤其影響到對時間要求嚴格的基因診斷。因此，市場收入潛力並非受限於需求不足，而是受限於這些高價值診斷服務支付的不確定性。

市場趨勢

人工智慧 (AI) 與突變分析的整合正在顯著改變市場格局，它解決了定序技術進步帶來的數據解讀瓶頸問題。隨著基因組數據呈指數級成長，實驗室擴大採用機器學習演算法來實現致病性分類的自動化，並優先識別致病突變，從而緩解「意義未明變異 (VUS)」這一普遍存在的挑戰。這項技術進步顯著縮短了診斷時間，提高了臨床診斷的準確性，尤其是在複雜遺傳疾病的診斷方面。

用於精確基因解讀的計算工具正迅速成熟，例如GoogleDeepMind的AlphaFold 3。截至2024年5月，該工具在蛋白質-DNA交互作用的預測準確率方面，相比其他專用工具提高了50%。同時，隨著新生兒基因組篩檢計畫的擴展，市場正經歷著向預防性人口健康管理的重大結構性轉變。公共衛生工作正日益將基因組定序與傳統的生化檢測相結合，甚至完全取代傳統的生化檢測，以篩檢更廣泛的、可治療的疾病。這一趨勢推動了市場成長，因為它需要高通量測序工作流程以及專注於早期疾病檢測的專用檢測項目，例如英國基因組學公司於2024年10月開展的針對200多種罕見遺傳疾病的新生兒篩檢試驗計畫。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：罕見疾病基因檢測的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 疾病類型（神經系統疾病、免疫系統疾病、血液系統疾病、內分泌及代謝性疾病、癌症、肌肉骨骼疾病、心血管疾病、皮膚疾病、其他）
    • 專業領域（分子遺傳檢測、染色體遺傳檢測、生化遺傳檢測）
    • 依技術分類（次世代定序(NGS)、全EXOME定序、全基因測序、晶片技術、基於 PCR 的檢測、FISH、Sanger定序、核型分析）
    • 依最終用戶（實驗室/CRO、醫院/診所、診斷檢測實驗室）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美罕見疾病基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲罕見疾病基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區罕見疾病基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲罕見疾病基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲罕見疾病基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球罕見疾病基因檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Centogene NV
  • Invitae Corp.
  • 3billion, Inc.
  • Eurofins Scientific SE
  • Strand Life Sciences Pvt Ltd
  • Ambry Genetics Corp.
  • Perkin Elmer, Inc.
  • Realm IDX, Inc.
  • Macrogen, Inc.
  • Baylor Miraca Genetics Laboratories, LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 15833

The Global Rare Disease Genetic Testing Market is projected to expand significantly, from USD 1.11 Billion in 2025 to USD 1.83 Billion by 2031, exhibiting an 8.69% Compound Annual Growth Rate. This market encompasses specialized diagnostic services and assays designed to analyze genetic material to pinpoint mutations linked to low-prevalence medical conditions. The primary catalysts for this growth are the swift decrease in genomic sequencing expenses and the pressing clinical need to provide definitive diagnoses for patients facing complex and lengthy diagnostic journeys.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.11 Billion
Market Size 2031USD 1.83 Billion
CAGR 2026-20318.69%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

The demand for these services is further bolstered by the vast number of rare and genetic diseases identified globally, exceeding 10,000 distinct types as of 2024, according to Global Genes. Despite this substantial growth potential, the market's progress is frequently hampered by considerable hurdles concerning reimbursement and coverage policies. Inconsistent payment structures and strict payer requirements often lead to denied claims or prohibitive out-of-pocket expenses for patients, thereby limiting access to essential diagnostic resources and decelerating the widespread commercial adoption of advanced testing panels.

Market Driver

The Global Rare Disease Genetic Testing Market is primarily driven by two key factors: substantial reductions in genomic sequencing costs and rapid advancements in Next-Generation Sequencing (NGS) technologies. These technological progress points have effectively removed financial obstacles, transforming high-throughput sequencing from a niche luxury into a standard diagnostic procedure. This shift is exemplified by the introduction of ultra-low-cost platforms, such as Ultima Genomics' UG 100 sequencer, launched in February 2024, which can deliver a $100 genome. This newfound affordability accelerates the widespread adoption of whole-genome sequencing (WGS), consequently boosting the global volume of processed samples.

This industrial-scale expansion is further demonstrated by major research centers like Regeneron's Genetics Center, which, by September 2024, had successfully sequenced over 2.5 million human exomes, indicating massive capacity growth in the sector. Concurrently, the market benefits from increased R&D investment in orphan drugs and companion diagnostics, stimulated by supportive government regulations. As regulatory agencies encourage the development of treatments for low-prevalence conditions, pharmaceutical companies are increasingly using genetic testing to identify rare mutations and effectively stratify patients for clinical trials. This is underscored by the U.S. FDA's January 2025 report on 2024 drug approvals, which showed that 52% of all novel drug approvals were for rare or orphan diseases, highlighting the essential role of robust companion diagnostics and genetic testing in delivering precision medicine to rare disease patients.

Market Challenge

The primary obstacle impeding the growth of the Global Rare Disease Genetic Testing Market consists of restrictive reimbursement policies and inconsistent coverage criteria. Insurers often categorize advanced genomic assays, including Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS), as experimental or investigational. This classification typically stems from a perceived absence of adequate clinical utility data, frequently leading to outright claim denials or the imposition of strict prior authorization prerequisites.

These challenges impose substantial financial risks on diagnostic laboratories and result in prohibitive out-of-pocket costs for patients. Such administrative barriers effectively disconnect the availability of advanced testing from patient access, causing healthcare providers to be reluctant in ordering comprehensive genetic panels that could resolve complex diagnostic journeys. The operational friction created by these coverage disputes significantly hinders commercial adoption, with the American Medical Association reporting in 2024 that 94% of physicians experienced delays in patient care due to prior authorization requirements, a systemic issue particularly impacting time-sensitive genetic diagnoses. Consequently, the market's revenue potential is constrained not by a lack of demand, but by the uncertainty surrounding payment for these high-value diagnostic services.

Market Trends

The integration of artificial intelligence (AI) into variant analysis is profoundly transforming the market by addressing data interpretation bottlenecks that persist despite advancements in sequencing technology. As the volume of genomic data grows exponentially, laboratories are increasingly adopting machine learning algorithms to automate the classification of pathogenicity and prioritize causal variants, thereby mitigating the pervasive challenge of variants of uncertain significance (VUS). This technological evolution substantially shortens diagnostic turnaround times and improves clinical precision, particularly for complex genetic cases.

The rapid maturation of computational tools essential for accurate genetic interpretation is evident in developments like Google DeepMind's AlphaFold 3, which, as of May 2024, demonstrated a 50% improvement in predicting protein-DNA interactions compared to specialized tools. Concurrently, the market is witnessing a significant structural shift towards proactive population health management through the expansion of genomic newborn screening panels. Public health initiatives are increasingly integrating or entirely replacing traditional biochemical assays with genomic sequencing to screen infants for a much wider array of treatable conditions. This trend stimulates market growth by requiring high-volume sequencing workflows and the development of specialized panels tailored for early disease detection, exemplified by Genomics England's October 2024 pilot program to screen newborns for over 200 rare genetic conditions.

Key Market Players

  • Centogene N.V.
  • Invitae Corp.
  • 3billion, Inc.
  • Eurofins Scientific SE
  • Strand Life Sciences Pvt Ltd
  • Ambry Genetics Corp.
  • Perkin Elmer, Inc.
  • Realm IDX, Inc.
  • Macrogen, Inc.
  • Baylor Miraca Genetics Laboratories, LLC

Report Scope

In this report, the Global Rare Disease Genetic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rare Disease Genetic Testing Market, By Disease Type

  • Neurological Disease
  • Immunological Disorders
  • Hematology Diseases
  • Endocrine & Metabolism Diseases
  • Cancer
  • Musculoskeletal Disorders
  • Cardiovascular Disorders (CVDs)
  • Dermatology Disease
  • Others

Rare Disease Genetic Testing Market, By Speciality

  • Molecular Genetic Tests
  • Chromosomal Genetic Tests
  • Biochemical Genetic Tests

Rare Disease Genetic Testing Market, By Technology

  • Next-Generation Sequencing (NGS)
  • Whole Exome Sequencing
  • Whole Genome Sequencing
  • Array Technology
  • PCR-based Testing
  • FISH
  • Sanger Sequencing
  • Karyotyping

Rare Disease Genetic Testing Market, By End User

  • Research Laboratories & CROs
  • Hospitals & Clinics
  • Diagnostic Laboratories

Rare Disease Genetic Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rare Disease Genetic Testing Market.

Available Customizations:

Global Rare Disease Genetic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rare Disease Genetic Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Neurological Disease, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders (CVDs), Dermatology Disease, Others)
    • 5.2.2. By Speciality (Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests)
    • 5.2.3. By Technology (Next-Generation Sequencing (NGS), Whole Exome Sequencing, Whole Genome Sequencing, Array Technology, PCR-based Testing, FISH, Sanger Sequencing, Karyotyping)
    • 5.2.4. By End User (Research Laboratories & CROs, Hospitals & Clinics, Diagnostic Laboratories)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Rare Disease Genetic Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Speciality
    • 6.2.3. By Technology
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Rare Disease Genetic Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Speciality
        • 6.3.1.2.3. By Technology
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Rare Disease Genetic Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Speciality
        • 6.3.2.2.3. By Technology
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Rare Disease Genetic Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Speciality
        • 6.3.3.2.3. By Technology
        • 6.3.3.2.4. By End User

7. Europe Rare Disease Genetic Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Speciality
    • 7.2.3. By Technology
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Rare Disease Genetic Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Speciality
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By End User
    • 7.3.2. France Rare Disease Genetic Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Speciality
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Rare Disease Genetic Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Speciality
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Rare Disease Genetic Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Speciality
        • 7.3.4.2.3. By Technology
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Rare Disease Genetic Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Speciality
        • 7.3.5.2.3. By Technology
        • 7.3.5.2.4. By End User

8. Asia Pacific Rare Disease Genetic Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Speciality
    • 8.2.3. By Technology
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Rare Disease Genetic Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Speciality
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By End User
    • 8.3.2. India Rare Disease Genetic Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Speciality
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Rare Disease Genetic Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Speciality
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Rare Disease Genetic Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Speciality
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Rare Disease Genetic Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Speciality
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By End User

9. Middle East & Africa Rare Disease Genetic Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Speciality
    • 9.2.3. By Technology
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Rare Disease Genetic Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Speciality
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Rare Disease Genetic Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Speciality
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Rare Disease Genetic Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Speciality
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By End User

10. South America Rare Disease Genetic Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Speciality
    • 10.2.3. By Technology
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Rare Disease Genetic Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Speciality
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Rare Disease Genetic Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Speciality
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Rare Disease Genetic Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Speciality
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Rare Disease Genetic Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Centogene N.V.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Invitae Corp.
  • 15.3. 3billion, Inc.
  • 15.4. Eurofins Scientific SE
  • 15.5. Strand Life Sciences Pvt Ltd
  • 15.6. Ambry Genetics Corp.
  • 15.7. Perkin Elmer, Inc.
  • 15.8. Realm IDX, Inc.
  • 15.9. Macrogen, Inc.
  • 15.10. Baylor Miraca Genetics Laboratories, LLC

16. Strategic Recommendations

17. About Us & Disclaimer